5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors
The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.
Abstract
A series of 5,6,7,8-tetrahydro-1,6-naphthyridine derivatives targeting the allosteric lens-epithelium-derived-growth-factor-p75 (LEDGF/p75)-binding site on HIV-1 integrase, an attractive target for antiviral chemotherapy, was prepared and screened for activity against HIV-1 infection in cell culture. Small molecules that bind within the LEDGF/p75-binding site promote aberrant multimerization of the integrase enzyme and are of significant interest as HIV-1-replication inhibitors. Structure-activity-relationship studies and rat pharmacokinetic studies of lead compounds are presented.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some of the residues that line the ALLINI binding pocket are highly polymorphic among circulating HIV-1 strains, inspiring efforts to design molecules that remain active in the face of such amino acid sequence variability186,187.”
From Structure and function of retroviral integrase (2022) · cites this paper as [187]
In the citing paper
“Many ALLINIs were co-crystallised with the isolated HIV-1 IN CCD, and the structures revealed the molecules grip onto the LEDGF/p75 IBD binding pocket at the IN CCD dimerization interface171,172,174,175,180,186,187.”
From Structure and function of retroviral integrase (2022) · cites this paper as [187]
Citations
Cites
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Gonzalez Paz, O., Hazuda, D. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800245z · Cited by 633
Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479
Brameld, K. A., Kuhn, B., Reuter, D. C., & Stahl, M. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci7002494 · Cited by 372
The mechanism of retroviral integration from X-ray structures of its key intermediates
Maertens, G. N., Hare, S., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature09517 · Cited by 296
Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01474-16 · Cited by 290
The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication
Engelman, A., & Cherepanov, P. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000046 · Cited by 231
HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
Blanco, J.-L., Varghese, V., Rhee, S.-Y., Gatell, J. M., & Shafer, R. W. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir025 · Cited by 218
Development of Antiretroviral Drug Resistance
Wainberg, M. A., Zaharatos, G. J., & Brenner, B. G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004180 · Cited by 215
Jurado, K. A., Wang, H., Slaughter, A., Feng, L., Kessl, J. J., Koh, Y., Wang, W., Ballandras-Colas, A., Patel, P. A., Fuchs, J. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300703110 · Cited by 203
Johns, B. A., Kawasuji, T., Weatherhead, J. G., Taishi, T., Temelkoff, D. P., Yoshida, H., Akiyama, T., Taoda, Y., Murai, H., Kiyama, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400645w · Cited by 186
Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
Fader, L. D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500002n · Cited by 178
Anderson, G. M., Kollman, P. A., Domelsmith, L. N., & Houk, K. N. (1979) · Journal of the American Chemical Society · doi:10.1021/ja00503a018 · Cited by 176
Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy
McColl, D. J., & Chen, X. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.11.004 · Cited by 173
Integrase, LEDGF/p75 and HIV replication
Poeschla, E. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7540-5 · Cited by 165
The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy
Christ, F., & Debyser, Z. (2012) · Virology · doi:10.1016/j.virol.2012.09.033 · Cited by 131
Le Rouzic, E., Bonnard, D., Chasset, S., Bruneau, J.-M., Chevreuil, F., Le Strat, F., Nguyen, J., Beauvoir, R., Amadori, C., Brias, J., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-144 · Cited by 127
Balakrishnan, M., Yant, S. R., Tsai, L., O’Sullivan, C., Bam, R. A., Tsai, A., Niedziela-Majka, A., Stray, K. M., Sakowicz, R., & Cihlar, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074163 · Cited by 126
Sato, M., Kawakami, H., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Matsuzaki, Y., Yamataka, K., Ikeda, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900460z · Cited by 109
Prospects for Treatment of Latent HIV
Barton, K., Burch, B. D., Soriano-Sarabia, N., & Margolis, D. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.202 · Cited by 101
Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
Fenwick, C., Amad, M., Bailey, M. D., Bethell, R., Bös, M., Bonneau, P., Cordingley, M., Coulombe, R., Duan, J., Edwards, P., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02719-13 · Cited by 99
LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014)
Demeulemeester, J., Chaltin, P., Marchand, A., De Maeyer, M., Debyser, Z., & Christ, F. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.898753 · Cited by 83
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
Novel therapeutic strategies targeting HIV integrase
Quashie, P. K., Sloan, R. D., & Wainberg, M. A. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-34 · Cited by 74
Ju, L., Lippert, A. R., & Bode, J. W. (2008) · Journal of the American Chemical Society · doi:10.1021/ja800053t · Cited by 74
Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor
Fandrick, K. R., Li, W., Zhang, Y., Tang, W., Gao, J., Rodriguez, S., Patel, N. D., Reeves, D. C., Wu, J., Sanyal, S., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501575 · Cited by 73
Cho, S. J., Jensen, N., Kurome, T., Kadari, S., Manzano, M. L., Malberg, J. E., Caldarone, B. J., Roth, B. L., & Kozikowski, A. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801354e · Cited by 63
New first and second generation inhibitors of human immunodeficiency virus-1 integrase
Pendri, A., Meanwell, N. A., Peese, K. M., & Walker, M. A. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.586631 · Cited by 60
Self-citation1 The Discovery of Raltegravir, an Integrase Inhibitor for the Treatment of HIV Infection
Rowley, M. (2008) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(07)00001-x · Cited by 58
Bryan, R. F., & Freyberg, D. P. (1975) · Journal of the Chemical Society Perkin Transactions 2 · doi:10.1039/p29750001835 · Cited by 46
HIV-1 Integrase Multimerization as a Therapeutic Target
Feng, L., Larue, R. C., Slaughter, A., Kessl, J. J., & Kvaratskhelia, M. (2015) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2015_439 · Cited by 45
Bonnard, D., Le Rouzic, E., Eiler, S., Amadori, C., Orlov, I., Bruneau, J.-M., Brias, J., Barbion, J., Chevreuil, F., Spehner, D., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816793 · Cited by 42
Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor
Fandrick, K. R., Li, W., Zhang, Y., Tang, W., Gao, J., Rodríguez, S., Patel, N. D., Reeves, D. C., Wu, J., Sanyal, S., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201501575 · Cited by 42
Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors
Jurado, K. A., & Engelman, A. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.15 · Cited by 40
Hummel, W., Huml, K., & Bürgi, H. (1988) · Helvetica Chimica Acta · doi:10.1002/hlca.19880710540 · Cited by 35
Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs
Fader, L. D., Bailey, M., Beaulieu, E., Bilodeau, F., Bonneau, P., Bousquet, Y., Carson, R. J., Chabot, C., Coulombe, R., Duan, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00194 · Cited by 26
Fader, L. D., Carson, R. J., Morin, S., Bilodeau, F., Chabot, C., Halmos, T., Bailey, M. D., Kawai, S. H., Coulombe, R., LaPlante, S. R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500110j · Cited by 24
Research works printed but not linked: 1
- Mitchell, M.; Balakrishnan, M.; Brizgys, G.; Cai, R.; Lansdon, E.; Mulato, A.; Osier, M.; Wang, J.; Yu, H.; Sakowicz, R. Novel non-catalytic site integrase inhibitor with improved resistance profile. Presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, Feb 13–16, 2017; Poster 434.
Cited by
Structure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Stereochemistry and Recent Applications of Axially Chiral Organic Molecules
Mancinelli, M., Bencivenni, G., Pecorari, D., & Mazzanti, A. (2020) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201901918 · Cited by 87
Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. N. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 78
Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Lima, L. M., Alves, M. A., & do Amaral, D. N. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190808145235 · Cited by 54
Li, K., Lv, Y., Lu, Z., Yun, X.-H., & Yan, S. (2021) · Green Synthesis and Catalysis · doi:10.1016/j.gresc.2021.10.008 · Cited by 36
Metadata
- Authors
- Peese, K. M., Allard, C. W., Connolly, T., Johnson, B. L., Li, C., Patel, M., Sorensen, M. E., Walker, M. A., Meanwell, N. A., McAuliffe, B., Minassian, B., Krystal, M., Parker, D. D., Lewis, H. A., Kish, K., Zhang, P., Nolte, R. T., Simmermacher, J., Jenkins, S., Cianci, C., & Naidu, B. N.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Peese, Kevin M.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-01-04
- Volume
- 62
- Issue
- 3
- Pages
- 1348-1361
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2911092752
- Cited by
- 39
- References
- 39
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 9 · 2021: 8 · 2020: 7 · 2019: 5
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- HIV-1 integrase inhibitors, allosteric inhibitors, integrase multimerization, antiviral agents, structure-activity relationship, pharmacokinetics, HIV-1 replication
- MeSH terms
- Allosteric Site, Humans, Naphthyridines, Virus Replication, HIV-1, HIV Infections, Crystallography, X-Ray, HIV Integrase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.